Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A289VV1
Mon, 25.10.2021
HAEMATO AG
DGAP-Media / 25.10.2021 / 10:25
HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its own portfolio with a botulinum toxin p [ … ]
Mon, 25.10.2021
HAEMATO AG
HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1) is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company H [ … ]
Wed, 08.09.2021
HAEMATO AG
First Berlin Equity Research hat ein Research Update zu HAEMATO AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 49,00 auf EUR 50,00.
Zusammenfassung:
Der Sechsmonatsbericht zeigte eine starke Umsatz- und Ergebnissteigerung,
die FBe bei weitem übertraf [ … ]
Wed, 11.08.2021
HAEMATO AG
______________________________________________________________________________
HAEMATO AG announces preliminary figures for Q2 2021: Increase in Q2 revenue by 41% and EBIT by 596% compared to the same quarter last year. Increase in revenue and profit expectation for 2021
- HAEMATO continues to grow strongly: in the second quarter of 2021, pre [ … ]
Fri, 04.06.2021
HAEMATO AG
First Berlin Equity Research hat ein Research Update zu HAEMATO AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 48,00 auf EUR 49,00.
Zusammenfassung:
Dank eines verbesserten Produktportfolios und einer Geschäftsausweitung
zeigten die Q1-Zahlen erneut, [ … ]
Mon, 31.05.2021
HAEMATO AG
______________________________________________________________________________
Corporate News of HAEMATO AG:
HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 million.
Berlin, 31.05.2021 - HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2 [ … ]
Tue, 04.05.2021
HAEMATO AG
Ad hoc of HAEMATO AG:
HAEMATO AG proposes dividend payment
The Supervisory Board of HAEMATO AG approved the Executive Board's proposal for the appropriation of profits at today's balance sheet meeting. The Executive Board and Supervisory Board will therefore propose a dividend of EUR 1.00 per dividend-bearing share at the Annual General Meeting [ … ]
Thu, 22.04.2021
HAEMATO AG
First Berlin Equity Research hat ein Research Update zu HAEMATO AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 48,00.
Zusammenfassung:
Die HAEMATO-Aktie legte seit Jahresbeginn aufgrund des positiven
Nachrichtenflusses um rund 20% zu. Das Unternehmen [ … ]
Wed, 21.04.2021
HAEMATO AG
Corporate News of HAEMATO AG:
According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million.
In the 2020 financial year, HAEMATO AG, Schoenefeld (ISIN: DE000289VV1), achieved IFRS consolidated revenues of EUR 23 [ … ]
Mon, 29.03.2021
HAEMATO AG
Ad hoc of HAEMATO AG:
HAEMATO AG successfully completes capital increase
March 29, 2021
HAEMATO AG (ISIN: DE000A289VV1, WKN: A289VV) has successfully completed the capital increase which was announced on March 24, 2021. The capital increase was oversubscribed..
The Company increased its share capital by € 475,391.00 to € 5,229,307.00 by issuin [ … ]